D. Boral Capital Reiterates “Buy” Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $14.00 price target on the stock.

NRSN has been the topic of several other reports. Wall Street Zen cut NeuroSense Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 8th. Noble Financial raised NeuroSense Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th. Finally, Zacks Research upgraded NeuroSense Therapeutics to a “hold” rating in a report on Wednesday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, NeuroSense Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NeuroSense Therapeutics Stock Up 5.2%

Shares of NeuroSense Therapeutics stock traded up $0.04 during trading hours on Monday, hitting $0.85. 158,659 shares of the company’s stock traded hands, compared to its average volume of 350,350. NeuroSense Therapeutics has a twelve month low of $0.76 and a twelve month high of $2.60. The stock has a 50 day simple moving average of $1.07 and a 200-day simple moving average of $1.40.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NRSN. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the third quarter worth about $26,000. Squarepoint Ops LLC lifted its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the second quarter worth about $54,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.